Where Clinical Relevance Meets Scalable Value
Our focus is on tangible interventions that fit seamlessly into clinical workflows, ultimately leading to enhanced health outcomes.
We believe long-term value creation in healthcare requires measurable adoption, operational integration, and clear impact.
Clinical Integration
Embedded solutions aligned with real-world healthcare workflows.
Measurable Outcomes
Clear data-backed improvements in efficiency and health impact.
Scalable Adoption
Defined path from validation to system-wide deployment.
Investing in Patient-Centric Innovation in Cancer and Cardiac Care
An impact-oriented venture fund backing capital-efficient healthcare companies that improve outcomes in cancer and cardiac disease while aligning with provider adoption and reimbursement realities.
Why Now
A capital gap in opportunities that matter most.
- Clinical need is undeniable
- Adoption incentives are aligned
- Capital scarcity creates attractive entry points
Cancer and cardiac disease account for nearly half of healthcare spending and remain the leading drivers of morbidity and mortality. Yet early-stage capital has shifted toward horizontal software, leaving clinically validated innovations underfunded.
Our Impact Focus
Purpose-driven, outcomes-oriented investing.
- Earlier diagnosis or intervention
- Care outside high-cost acute settings
- Reduced treatment burden with maintained outcomes
- Clinical benefit aligned with cost reduction
Impact is not a separate goal—it is fundamental to how we invest.
Investment Thesis
Adoption over novelty.
- Clearly defined cancer or cardiac use cases
- Identifiable buyer & reimbursement pathway
- Value milestones with disciplined capital deployment
We believe capital efficiency and clinical relevance are the primary drivers of durable value in healthcare.
Fund Highlights
Structural clarity. Disciplined deployment. Institutional alignment.
Overview
Hover to explore →
Health Innovation Partners I
- Size: $150M – $200M
- Expected ROI: 3–5X
- Initial Investment Period: 5 years
Investment Plan
Hover to explore →
Therapeutic Areas
≤60% Cancer
≤50% Cardiac
≤20% Other
Investment Size
$3M – $10M Initial
$15M – $20M Max
Criteria
Hover to explore →
Must improve access or delivery without budget increase. Focus on:
Pharmaceuticals
6 months to IND – Phase 1 completion
Devices
Feasibility to Launch
Focus
Hover to explore →
Stage: Seed to Series B
Core Sectors:
- Cancer and cardiac therapeutics
- Devices & disease management
- Decentralized & home-based care
- Clinical workflow tools
What We Avoid
Hover to explore →
Purely speculative science
Long regulatory timelines without reimbursement clarity
Capital-intensive models without near-term adoption
Alignment
Hover to explore →
Meaningful GP commitment alongside LP capital
Institutional fund structure & reporting
Long-term orientation aligned with patient outcomes
We seek:
Purpose-driven healthcare exposure
Disciplined cancer and cardiac exposure
Transparent communication & access
Investor & Impact Disclosure
This material is provided for informational purposes only and does not constitute an offer to invest. Any investment will be made solely pursuant to definitive offering documents.
Impact objectives are pursued alongside financial objectives; however, there can be no guarantee that any particular impact or financial outcome will be achieved.